Clinical Trials Logo
  1. Home
  2. Influenza A Virus Infection
  3. NCT01459081

Efficacy and Safety of Inhaled Zanamivir in Treatment of Influenza A and B Virus Infections in China

Influenza A Virus Infection Clinical Trial

Official title:
Randomised, Double-blind, Placebo-controlled Trial of Inhaled Zanamivir in Treatment of Influenza A and B Virus Infections in China

Clinical Trial Summary

The aim of this study is to evaluate the clinical efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections in China.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01459081
Study type Interventional
Source Jiangsu Simcere Pharmaceutical Co., Ltd.
Contact
Status Completed
Phase Phase 3
Start date October 2011
Completion date December 2012
View Details
See also
  Status Clinical Trial Phase
Completed NCT02250274 - Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents Phase 4
Completed NCT01175122 - Evaluation of the Safety and Immunogenicity of a Live Attenuated Virus Vaccine for the Prevention of H2N3 Influenza Phase 1
Completed NCT00985582 - Antiviral Therapy for Influenza A H1N1 N/A
Completed NCT00984451 - A Pilot Study for Collection of Anti-Influenza A Immune Plasma
Completed NCT03651544 - The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac Phase 1
Completed NCT02572817 - Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A Phase 3
Withdrawn NCT00844155 - Study of the Relative Oral Bioavailability of the Antiflu Medicine Oseltamivir in the Intensive Care Unit N/A
Completed NCT00491985 - Safety and Immunogenicity of 2 Formulations of an Intramuscular A/H5N1 Pandemic Influenza Vaccine in Children Phase 2
Completed NCT01146535 - Interferon Alpha Lozenges Plus Oseltamivir for Influenza Treatment Phase 2
Completed NCT00457509 - Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults Phase 1
Completed NCT01546506 - Confirmation of the Antiviral Effects of Midodrine Identified With a Gene Expression Signature-based Screening of Inluenza A Virus Infected Cells Phase 2
Completed NCT01136057 - Blood and Plasma Collection For Use in Future Clinical Trials